Telix Pharmaceuticals has signed a conditional non-binding term sheet to acquire QSAM Biosciences in a deal worth up to $125m. The term sheet agreement also includes the acquisition of QSAM’s lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback